Furthermore, AstraZeneca can make payments as high as $225 million if and when certain resources are subsequently transferred. The Bristol-Myers Squibb Panel of Directors has accepted this transaction. The business also offered 2014 non-GAAP EPS assistance of $1.65 to $1.80. There is absolutely no readily reliable or accessible comparable GAAP measure because of this non-GAAP EPS information at this time. This agreement allows us to further evolve our business model as a leading specialty BioPharma business and increase resources behind the possibilities that drive the greatest long-term value for patients, our organization and our shareholders, stated Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. Today’s announcement places the diabetes franchise in the able hands of AstraZeneca and we can move to a more simplified working model consistent with our pipeline and portfolio.Body temperature returned on track within 36 hours following the begin of treatment in 82 % of babies, and within 48 hours in 87 %. Related StoriesCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyAustralian experts find a way to improve cross-protective capabilities of influenza A vaccineJohns Hopkins doctors urge people to get vaccinated against influenza virusAbout half of the infants experienced some type of complication, although most were not serious. Most of the infants developed feeding problems, requiring intravenous fluids often. A few required antibiotics for secondary bacterial infections. More Research Needed to Evaluate Antiviral Drugs for Infants Oseltamivir has been suggested for treatment and avoidance of influenza in children who are 1 to 12 years of age, and also in adults.